Eli Lilly and CoXSWX:LLY 99 Graham Number is CHF90.74 as of Mar. 2026, which is 100% below its 10-year median of 8.03. GuruFocus rates XSWX:LLY with a GF Score™ of 99/100 and a GF Value™ of CHF1,132.28 (Modestly Undervalued). The stock has 6 warning signs investors should review. Among 600 Drug Manufacturers companies, Eli Lilly and Co ranks worse than 97.17% on this metric.
Graham Number is a figure that measures a stock's fundamental value by taking into account the company's earnings per share and book value per share. The Graham number is the upper bound of the price range that a defensive investor should pay for the stock. According to the theory, any stock price below the Graham number is considered undervalued, and thus worth investing in.
As of today (2026-07-05), the stock price of Eli Lilly and Co is CHF970.00. Eli Lilly and Co's graham number for the quarter that ended in Mar. 2026 was CHF90.74. Therefore, Eli Lilly and Co's Price to Graham Number ratio for today is 10.69.
The historical rank and industry rank for Eli Lilly and Co's Graham Number or its related term are showing as below:
XSWX:LLY'
s Price-to-Graham-Number Range Over the Past 10 Years
Min: 3.25 Med: 8.03 Max: 149.97
Current: 10.6
During the past 13 years, the highest Price to Graham Number ratio of Eli Lilly and Co was 149.97. The lowest was 3.25. And the median was 8.03.
XSWX:LLY's Price-to-Graham-Number is ranked worse than 97.17% of 600
companies
in the Drug Manufacturers industry
Industry Median: 1.53
vs XSWX:LLY: 10.60
Graham Number is a combination of asset valuation and earnings power valuation. It is a very conservative way of valuing a stock.
Eli Lilly and Co (XSWX:LLY) Graham Number Explanation
Ben Graham actually did not publish a formula like this. But he wrote in The Intelligent Investor (1948 version) regarding to the criteria for purchases:
Current price should not be more than 15 times average earnings of the past three years.
Current price should not be more than 1.5 times the book value last reported. However, a multiplier of earnings below 15 could justify a correspondingly higher multiplier of assets. As a rule of thumb we suggest that the product of the multiplier times the ratio of price to book value should not exceed 22.5. (This figure corresponds to 15 times earnings and 1.5 times book value. It would admit an issue selling at only 9 times earnings and 2.5 times asset value, etc.)
Unlike valuation methods such as DCF or Discounted Earnings, the Graham number does not take growth into the valuation. Unlike the valuation methods based on book value alone, it takes into account the earnings power. Therefore, the Graham Number is a combination of asset valuation and earnings power valuation.
In general, the Graham number is a very conservative way of valuing a stock. It cannot be applied to companies with negative book values.
Eli Lilly and Co's Price to Graham number Ratio for today is calculated as
Price to Graham number
=
Share Price (Today)
/
Graham number (Q: Mar. 2026 )
=
970.00
/
90.74
=
10.69
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Be Aware
Please keep these in mind:
1. Graham Number does not take growth into account. Therefore it underestimates the values of the companies that have good earnings growth. We feel that if the earnings per share grows more than 10% a year, Graham Number underestimates the value.
2. Graham Number punishes the companies that have temporarily low earnings. Therefore, an average of earnings makes more sense in the calculation of Graham Number.
3. Graham Numbers underestimates companies that are light with book.
Eli Lilly and Co Graham Number Related Terms
Eli Lilly and Co Graham Number Historical Data
* Premium members only.
The historical data trend for Eli Lilly and Co's Graham Number can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
XSWX:LLY vs JNJ, ABBV, MRK: Graham Number Comparison
For the Drug Manufacturers - General subindustry, Eli Lilly and Co's Price-to-Graham-Number, along with its competitors' market caps and Price-to-Graham-Number data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Eli Lilly and Co Price-to-Graham-Number vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Eli Lilly and Co's Price-to-Graham-Number distribution charts can be found below:
* The bar in red indicates where Eli Lilly and Co's Price-to-Graham-Number falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Eli Lilly and Co (XSWX:LLY) has a Graham Number of CHF90.74 as of Mar. 2026. The Graham Number values a company based on its per-share earnings and book value. View historical data on Eli Lilly and Co and its competitors. This is 1030% above median its historical median of 8.03. Over the past decade, Eli Lilly and Co's Graham Number has ranged from 3.25 to 149.97. According to the industry distribution chart, Eli Lilly and Co ranks #583 out of 600 companies in the Drug Manufacturers industry, placing it in the top 97.2%.
Is Eli Lilly and Co's Graham Number too high?
Eli Lilly and Co's current Graham Number of CHF90.74 is 1030% above median its 10-year median of 8.03. Over the past 10 years, this metric has ranged from a low of 3.25 to a high of 149.97. Based on the distribution chart, Eli Lilly and Co ranks #583 out of 600 companies in the Drug Manufacturers industry, which is in the bottom quartile relative to peers. Overall, Eli Lilly and Co has a GF Score™ of 99/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Eli Lilly and Co's Graham Number compare to JNJ and ABBV?
According to the Drug Manufacturers industry distribution chart, Eli Lilly and Co ranks #583 out of 600 companies for Graham Number. This places Eli Lilly and Co in the lower half of its industry. The industry median Graham Number is 1.53. Historically, Eli Lilly and Co's own Graham Number has ranged from 3.25 to 149.97 over the past decade. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Graham Number for a Drug Manufacturers company?
The median Graham Number among Drug Manufacturers companies is 1.53, based on 600 companies in the industry. Companies in the top quartile (top 25%) have a Graham Number significantly above this median, while those in the bottom quartile fall well below. However, Graham Number should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Graham Number mean?
A high Graham Number can signal that a stock is expensive relative to its fundamentals. The Graham Number values a company based on its per-share earnings and book value. View historical data on Eli Lilly and Co and its competitors. For the Drug Manufacturers industry, the median Graham Number is 1.53 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Eli Lilly and Co's current Graham Number is CHF90.74, which is 1030% above median its own 10-year median of 8.03. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Eli Lilly and Co stock overvalued right now?
Based on GuruFocus' analysis, Eli Lilly and Co (XSWX:LLY) is currently considered Modestly Undervalued. The stock's GF Value™ is CHF1,132.28, compared to a current price of CHF970.00 — trading 14.3% below its estimated fair value. The current Graham Number is CHF90.74, which is 1030% above median its 10-year median of 8.03. Eli Lilly and Co's overall GF Score™ is 99/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Graham Number calculated?
Graham Number is calculated from a company's financial statements. For Eli Lilly and Co (XSWX:LLY), the current Graham Number is CHF90.74 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Eli Lilly and Co (XSWX:LLY) Overvalued in 2026?
Based on GuruFocus' analysis, Eli Lilly and Co stock appears to be undervalued.
The current stock price of CHF970.00 is trading 14.3% below its estimated GF Value™ of CHF1,132.28.
GuruFocus considers Eli Lilly and Co to be Modestly Undervalued.
Key valuation signals for XSWX:LLY:
Graham Number: CHF90.74 (1030% above median its 10-year median of 8.03)
GF Value™: CHF1,132.28 vs. price of CHF970.00 (14.3% below fair value)
No single metric tells the full story. See the XSWX:LLY stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Eli Lilly is a drug firm with a focus on neuroscience, cardiometabolic, cancer, and immunology. Lilly's key products include Verzenio and Jaypirca for cancer; Mounjaro, Zepbound, Foundayo, Jardiance, Trulicity, Humalog, and Humulin for cardiometabolic; and Taltz and Olumiant for immunology.
99GF Score
Get the complete analysis for XSWX:LLY
Graham Number is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
XSWX:LLY has been successfully added to your 
